DETAILS, FICTION AND CLINICAL EFFECTIVENESS OF ABBV-744 IN AML PATIENTS

In Phase A, individuals will receive distinctive doses and schedules of oral ABBV-744 pill to discover Risk-free dosing regimen. Further participants will probably be enrolled on the identified monotherapy dosign program. In Segment B, contributors will obtain oral ruxolitinib and ABBV-744 will probably be given as "increase-on" therapy. In Section